Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients

By  

Acta Haematologica, Vol. 112, Iss. 4, 2004-11 ,pp. : 179-183

Karger

Access to resources Recommend Favorite

Combined Chelation Therapy with Daily Oral Deferiprone and Twice-Weekly Subcutaneous Infusion of Desferrioxamine in Children with β-Thalassemia: 3-Year Experience

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 226-236

Karger

Access to resources Recommend Favorite

Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion‐dependent thalassemia: A randomized controlled trial

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 262-268

John Wiley & Sons Inc

Access to resources Recommend Favorite

Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

By Scalone Luciana   Mantovani Lorenzo G.   Krol Marieke   Rofail Diana   Ravera Simona   Grazia Bisconte Maria   Borgna-Pignatti Caterina   Borsellino Zelia   Cianciulli Paolo   Gallisai Domenico   Prossomariti Luciano   Stefàno Ippazio   Cappellini Maria D.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1905-1917

Informa Healthcare

Access to resources Recommend Favorite